Moleculin Biotech Stock Current Liabilities
| MBRX Stock | USD 1.09 0.05 4.81% |
Moleculin Biotech fundamentals help investors to digest information that contributes to Moleculin Biotech's financial success or failures. It also enables traders to predict the movement of Moleculin Stock. The fundamental analysis module provides a way to measure Moleculin Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Moleculin Biotech stock.
Total Current Liabilities is likely to drop to about 3.9 M in 2025. Non Current Liabilities Total is likely to drop to about 3.2 M in 2025. Moleculin | Current Liabilities |
Moleculin Biotech Company Current Liabilities Analysis
Moleculin Biotech's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Moleculin Biotech Current Liabilities | 772.79 K |
Most of Moleculin Biotech's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Moleculin Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Moleculin Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Moleculin Biotech is extremely important. It helps to project a fair market value of Moleculin Stock properly, considering its historical fundamentals such as Current Liabilities. Since Moleculin Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Moleculin Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Moleculin Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Moleculin Current Liabilities Historical Pattern
Today, most investors in Moleculin Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Moleculin Biotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Moleculin Biotech current liabilities as a starting point in their analysis.
Moleculin Biotech Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Moleculin Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Moleculin Biotech has a Current Liabilities of 772.79 K. This is 99.96% lower than that of the Biotechnology sector and 99.86% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.99% higher than that of the company.
Moleculin Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Moleculin Biotech's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Moleculin Biotech could also be used in its relative valuation, which is a method of valuing Moleculin Biotech by comparing valuation metrics of similar companies.Moleculin Biotech is currently under evaluation in current liabilities category among its peers.
Moleculin Fundamentals
| Return On Equity | -1.41 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 5.48 M | ||||
| Shares Outstanding | 13.3 M | ||||
| Shares Owned By Insiders | 0.75 % | ||||
| Shares Owned By Institutions | 3.49 % | ||||
| Number Of Shares Shorted | 2.2 M | ||||
| Price To Earning | (3.81) X | ||||
| Price To Book | 1.94 X | ||||
| EBITDA | (26.52 M) | ||||
| Net Income | (21.76 M) | ||||
| Cash And Equivalents | 58 M | ||||
| Cash Per Share | 2.03 X | ||||
| Total Debt | 358 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 10.47 X | ||||
| Book Value Per Share | 2.49 X | ||||
| Cash Flow From Operations | (23.86 M) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | (12.04) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 18 | ||||
| Beta | 1.94 | ||||
| Market Capitalization | 14.5 M | ||||
| Total Asset | 16.93 M | ||||
| Retained Earnings | (153.37 M) | ||||
| Working Capital | 19.46 M | ||||
| Current Asset | 28.09 K | ||||
| Current Liabilities | 772.79 K | ||||
| Net Asset | 16.93 M |
About Moleculin Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Moleculin Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Moleculin Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Moleculin Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.